Wolff-Parkinson-White syndrome consensus statement: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(6 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{Wolff-Parkinson-White syndrome}}
{{Wolff-Parkinson-White syndrome}}
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}; [[User:Kashish Goel|Kashish Goel, M.D.]]
{{CMG}}; '''Associate Editor-In-Chief:''' {{Sara.Zand}} {{CZ}}; [[User:Kashish Goel|Kashish Goel, M.D.]]




== Recommendations for Management of Asymptomatic Patients With Asymptomatic pre-excitation ==  
== Recommendations for Management of Asymptomatic Patients With Asymptomatic pre-excitation ==  
<ref name="PageJoglar2016">{{cite journal|last1=Page|first1=Richard L.|last2=Joglar|first2=José A.|last3=Caldwell|first3=Mary A.|last4=Calkins|first4=Hugh|last5=Conti|first5=Jamie B.|last6=Deal|first6=Barbara J.|last7=Estes III|first7=N.A. Mark|last8=Field|first8=Michael E.|last9=Goldberger|first9=Zachary D.|last10=Hammill|first10=Stephen C.|last11=Indik|first11=Julia H.|last12=Lindsay|first12=Bruce D.|last13=Olshansky|first13=Brian|last14=Russo|first14=Andrea M.|last15=Shen|first15=Win-Kuang|last16=Tracy|first16=Cynthia M.|last17=Al-Khatib|first17=Sana M.|title=2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia|journal=Heart Rhythm|volume=13|issue=4|year=2016|pages=e136–e221|issn=15475271|doi=10.1016/j.hrthm.2015.09.019}}</ref>
* '''2015 ACC-AHA Guideline'''<ref name="PageJoglar2016">{{cite journal|last1=Page|first1=Richard L.|last2=Joglar|first2=José A.|last3=Caldwell|first3=Mary A.|last4=Calkins|first4=Hugh|last5=Conti|first5=Jamie B.|last6=Deal|first6=Barbara J.|last7=Estes III|first7=N.A. Mark|last8=Field|first8=Michael E.|last9=Goldberger|first9=Zachary D.|last10=Hammill|first10=Stephen C.|last11=Indik|first11=Julia H.|last12=Lindsay|first12=Bruce D.|last13=Olshansky|first13=Brian|last14=Russo|first14=Andrea M.|last15=Shen|first15=Win-Kuang|last16=Tracy|first16=Cynthia M.|last17=Al-Khatib|first17=Sana M.|title=2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia|journal=Heart Rhythm|volume=13|issue=4|year=2016|pages=e136–e221|issn=15475271|doi=10.1016/j.hrthm.2015.09.019}}</ref>


{| class="wikitable"
{| class="wikitable"
|-
|-
! The class of Recommendation(COR) !! Recommendations
! Class of Recommendation(COR) !! Recommendations
|-
|-
|    1    || In asymptomatic patients with pre-excitation, the findings of abrupt loss of conduction over
|    1    || In asymptomatic patients with pre-excitation, the findings of abrupt loss of conduction over
Line 29: Line 29:




== Recommendations for Management of Symptomatic Patients With Manifest Accessory Pathways ==
* '''2015 ACC-AHA Guideline'''<ref name="PageJoglar2016">{{cite journal|last1=Page|first1=Richard L.|last2=Joglar|first2=José A.|last3=Caldwell|first3=Mary A.|last4=Calkins|first4=Hugh|last5=Conti|first5=Jamie B.|last6=Deal|first6=Barbara J.|last7=Estes III|first7=N.A. Mark|last8=Field|first8=Michael E.|last9=Goldberger|first9=Zachary D.|last10=Hammill|first10=Stephen C.|last11=Indik|first11=Julia H.|last12=Lindsay|first12=Bruce D.|last13=Olshansky|first13=Brian|last14=Russo|first14=Andrea M.|last15=Shen|first15=Win-Kuang|last16=Tracy|first16=Cynthia M.|last17=Al-Khatib|first17=Sana M.|title=2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia|journal=Heart Rhythm|volume=13|issue=4|year=2016|pages=e136–e221|issn=15475271|doi=10.1016/j.hrthm.2015.09.019}}</ref>


 
{| class="wikitable"
|-
! Class of Recommendation !! Recommendations
|-
| 1 || In symptomatic patients with [[pre-excitation]], the findings of abrupt loss of conduction over the
pathway during [[exercise testing]] in [[sinus rhythm]] or intermittent loss
of [[pre-excitation]] during [[ECG]] or ambulatory monitoring are useful for
identifying patients at lower risk of developing rapid conduction over the[[ pathway]]
|-
| 1 || An EP study is useful in symptomatic patients with [[pre-excitation]] to risk-stratify for
life-threatening [[arrhythmic]] events
|}


==References==
==References==

Latest revision as of 06:24, 15 September 2020

Wolff-Parkinson-White syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Wolff-Parkinson-White syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Approach

History and Symptoms

Electrocardiogram

EKG Examples

Other Diagnostic Studies

Treatment

Risk Stratification

Cardioversion

Medical Therapy

Catheter Ablation

Prophylaxis

Consensus Statement

Case Studies

Case #1

Wolff-Parkinson-White syndrome consensus statement On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Wolff-Parkinson-White syndrome consensus statement

CDC onWolff-Parkinson-White syndrome consensus statement

Wolff-Parkinson-White syndrome consensus statement in the news

Blogs on Wolff-Parkinson-White syndrome consensus statement

Directions to Hospitals Treating Deep vein thrombosis

Risk calculators and risk factors for Wolff-Parkinson-White syndrome consensus statement

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Sara Zand, M.D.[2] Cafer Zorkun, M.D., Ph.D. [3]; Kashish Goel, M.D.


Recommendations for Management of Asymptomatic Patients With Asymptomatic pre-excitation

  • 2015 ACC-AHA Guideline[1]
Class of Recommendation(COR) Recommendations
1 In asymptomatic patients with pre-excitation, the findings of abrupt loss of conduction over

manifest pathway during exercise testing in sinus rhythm or intermittent loss of-excitation during ECG or ambulatory monitoring is useful to identify patients at low risk of rapid conduction over the pathway

2a An EP study is reasonable in asymptomatic patients with pre-excitation to risk-stratify for

arrhythmic events

2a Catheter ablation of the accessory pathway is reasonable in asymptomatic patients with pre-

excitation if an EP study identifies a high risk of arrhythmic events, including rapidly conducting pre-excited AF

2a Catheter ablation of the accessory pathway is reasonable in asymptomatic patients if the presence of

pre-excitation precludes specific employment(such as with pilots)

2a Observation,without further evaluation or treatment,is reasonable in asymptomatic patients

with pre-excitation


Recommendations for Management of Symptomatic Patients With Manifest Accessory Pathways

  • 2015 ACC-AHA Guideline[1]
Class of Recommendation Recommendations
1 In symptomatic patients with pre-excitation, the findings of abrupt loss of conduction over the

pathway during exercise testing in sinus rhythm or intermittent loss of pre-excitation during ECG or ambulatory monitoring are useful for identifying patients at lower risk of developing rapid conduction over thepathway

1 An EP study is useful in symptomatic patients with pre-excitation to risk-stratify for

life-threatening arrhythmic events

References

  1. 1.0 1.1 Page, Richard L.; Joglar, José A.; Caldwell, Mary A.; Calkins, Hugh; Conti, Jamie B.; Deal, Barbara J.; Estes III, N.A. Mark; Field, Michael E.; Goldberger, Zachary D.; Hammill, Stephen C.; Indik, Julia H.; Lindsay, Bruce D.; Olshansky, Brian; Russo, Andrea M.; Shen, Win-Kuang; Tracy, Cynthia M.; Al-Khatib, Sana M. (2016). "2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia". Heart Rhythm. 13 (4): e136–e221. doi:10.1016/j.hrthm.2015.09.019. ISSN 1547-5271.

Template:WH Template:WS